| Literature DB >> 35621980 |
Ganiyu Akinniyi1, Jeonghee Lee1, Hiyoung Kim2, Joon-Goo Lee3, Inho Yang1.
Abstract
Ipomoea pes-caprae (Linn.) R. Br. (Convolvulaceae) is a halophytic plant that favorably grows in tropical and subtropical countries in Asia, America, Africa, and Australia. Even though this plant is considered a pan-tropical plant, I. pes-caprae has been found to occur in inland habitats and coasts of wider areas, such as Spain, Anguilla, South Africa, and Marshall Island, either through a purposeful introduction, accidentally by dispersal, or by spreading due to climate change. The plant parts are used in traditional medicine for treating a wide range of diseases, such as inflammation, gastrointestinal disorders, pain, and hypertension. Previous phytochemical analyses of the plant have revealed pharmacologically active components, such as alkaloids, glycosides, steroids, terpenoids, and flavonoids. These phytoconstituents are responsible for the wide range of biological activities possessed by I. pes-caprae plant parts and extracts. This review arranges the previous reports on the botany, distribution, traditional uses, chemical constituents, and biological activities of I. pes-caprae to facilitate further studies that would lead to the discovery of novel bioactive natural products from this halophyte.Entities:
Keywords: Ipomoea pes-caprae; halophyte; halophyte natural products; phytochemistry; traditional medicine
Mesh:
Substances:
Year: 2022 PMID: 35621980 PMCID: PMC9144928 DOI: 10.3390/md20050329
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 6.085
Figure 1A map showing the global distribution of I. pes-caprae.
Figure 2The alkaloid (1) from I. pes-caprae.
Figure 3The norisoprenoids (2 and 3) from I. pes-caprae.
Figure 4The flavonoids (4–10) and coumarin (11) from I. pes-caprae.
Figure 5Other phenols (12–26) from I. pes-caprae.
Figure 6The terpenoids (27–53) from I. pes-caprae.
Figure 7The steroids (54 and 55) from I. pes-caprae.
Figure 8The glycosides (56–91) from I. pes-caprae.
Figure 9Other compounds (92 and 93) from I. pes-caprae.
Antioxidant activity of I. pes-caprae natural products.
| Compound | Pharmacological Activities | Reference |
|---|---|---|
|
| DPPH * scavenging (IC50 ** = 0.032 μM) | [ |
|
| DPPH assay (RC50 *** = 0.048 µM) | [ |
|
| DPPH scavenging (IC50 = 0.028 µM) | [ |
|
| DPPH scavenging (IC50 = 10.45 µM) | [ |
|
| DPPH scavenging (IC50 = 3.29 µM) | [ |
|
| DPPH scavenging (IC50 = 3.79 µM) | [ |
| DPPH scavenging (IC50 = 0.033 µM) | [ | |
| Superoxide radical scavenging (IC50 = 0.190 μM) | [ | |
| DPPH scavenging (IC50 = 1.25 μM) | [ | |
| DPPH scavenging (IC50 = 0.338 µM) | [ |
* DPPH: 2,2-diphenyl-1-picrylhydrazyl; ** IC50: half-maximal inhibitory concentration; *** RC50: half-maximal radical scavenging concentration; **** FRAP: ferric-reducing antioxidant power; ***** ABTS: 2,2′-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid).
Anti-inflammatory activity of I. pes-caprae natural products.
| Compound | Pharmacological Activities | Reference |
|---|---|---|
| 1.0 mg/ear produced 35% inhibition of oedema formation | [ | |
|
| Inhibitory effect on NO * production IC50 ** = 37.1 µM | [ |
| Inhibition of prostaglandin synthesis IC50 = 340 µM | [ | |
| 1.0 mg/ear produced 38% inhibition of oedema formation. Inhibition of prostaglandin synthesis IC50 = 9.2 µM | [ | |
|
| Inhibition of prostaglandin synthesis IC50 = 18 µM | [ |
|
| 0.6 mg/ear produced 30% inhibition of oedema formation. Inhibition of prostaglandin synthesis IC50 = 230 µM | [ |
| 1.0 mg/ear produced 47% inhibition of oedema formation | [ | |
| Inhibited writhing response by 75.19% at 25 mg/kg body weight | [ | |
| 4 mg/100g i.p. **** produced 19.1% inhibition | [ | |
| 4 mg/100g i.p. produced 43.6% inhibition | [ |
* NO: nitric oxide; ** IC50: half-maximal inhibitory concentration; *** TNF-α: tumor necrosis factor-α; **** i.p.: intraperitoneal.
Antinociceptive activity of I. pes-caprae natural products.
| Compound | Pharmacological Activities | Reference |
|---|---|---|
|
| 10 mg/kg i.p. * inhibited constriction by 34.5% | [ |
| 10 mg/kg i.p. inhibited constriction by 54.4% | ||
| 10 mg/kg i.p. inhibited constriction by 88.1% | ||
| 10 mg/kg i.p. inhibited constriction by 75.5% |
* i.p: intraperitoneal.
Antimicrobial activity of I. pes-caprae natural products.
| Compound | Pharmacological Activities | Reference |
|---|---|---|
| MIC * value of 0.057 µM against | [ | |
| MIC value of 1.421 μM against | [ | |
| MIC50 ** value of 0.219 µM against | [ | |
| MIC value of 3 μM against | [ | |
| MIC value of 0.135 µM against | [ | |
| 0.048 μM produced inhibition zones of 14 mm ( | [ | |
| MIC value of 0.255 µM against | [ |
* MIC: minimum inhibitory concentration; ** MIC50: half-maximal minimum inhibitory concentration.
Collagenase inhibitory activity of I. pes-caprae natural products.
| Compound | Collagenase Inhibitory Activity IC50 * Value (µM) | Reference |
|---|---|---|
|
| 19.1 | [ |
|
| 14.2 | |
| 23.6 | ||
|
| 5.8 | |
| 31.7 | ||
|
| 16.2 | |
| 37.2 | ||
|
| 26.6 | |
| 82.7 |
* IC50: half-maximal inhibitory concentration.
Antispasmodic activity of I. pes-caprae natural products.
| Compound Name | Pharmacological Activities | Reference |
|---|---|---|
| 0.105 µM produced 41% inhibition on submaximal contractions of | [ | |
| 0.163 µM produced 45% inhibitions respectively of submaximal contractions of guinea-pig ileal smooth muscle | ||
| Inhibition of acetylcholine-induced contraction in guinea-pig ileum | [ |
* IC50: half-maximal inhibitory concentration.
Anticancer, antitumor, and antiproliferative activities of I. pes-caprae natural products.
| Compound | Pharmacological Activities | Reference |
|---|---|---|
|
| Decreased HCT116 * cell viability up to 30% after 24 h of treatment (IC50 ** = 0.055 μM) | [ |
|
| Inhibition of the growth of HL-60 *** cells (IC50 = 7.7 μM) | [ |
| Inhibition of the proliferation of A549 **** cells (IC50 = 0.162 μM) | [ | |
| Inhibition of the proliferation of A549 cells (IC50 = 0.333 μM) | [ | |
| Inhibition of the proliferation of A549 cells (IC50 = 0.162 µM) | [ | |
| Inhibition of the proliferation of A549 (IC50 = 0.022) and | [ | |
| Inhibition of the proliferation of A549 cells (IC50 = 0.919 μM) | [ | |
| Selective anti-proliferative effect against HCT116 (IC50 = 19 µM) and | [ | |
| Inhibition of proliferation and | [ | |
| Inhibition of the proliferation of HepG2 ******** (IC50 = 0.017 μM) and | [ | |
| Weak cytotoxicity against nasopharyngeal, colon, squamous cell cervical, and ovarian carcinomas (ED50 ********** = 5–20 µg/mL) | [ | |
|
| 45.2% inhibition of the growth of human lung cancer cell A549 at 0.275 µM | [ |
* HCT116: human colorectal carcinoma cell lines; ** IC50: half-maximal inhibitory concentration; *** HL-60: human leukemia cell lines; **** A549: human lung cancer cell lines; ***** A2780: human ovarian carcinoma cell lines; ****** PANC-1: human pancreatic cancer cell lines; ******* SNU-1: human stomach cancer cell lines; ******** HepG2: human liver cancer cell lines; ********* Huh7: human liver carcinoma cell lines; ********** ED50: median effective dose.
Multidrug resistance efflux inhibiting activity of I. pes-caprae natural products.
| Compound | Pharmacological Activities | Reference |
|---|---|---|
| Multidrug-resistance inhibition against | [ | |
| Multidrug-resistance inhibitory effect against MCF-7/ADR ** cells. A total of 5 μg/mL of each compound potentiated the doxorubicin effect by 1.5–3.7-fold, producing IC50 *** values of 1.76, 3.98, 2.00, 3.20, 2.83, 1.58, 3.12, 2.57, 1.82, and 2.60 μg/mL for compounds 82–91, respectively | [ |
* MIC: minimum inhibitory concentration; ** MCF-7/ADR: adriamycin (adriacin doxorubicin, ADR)-resistant human breast cancer cell lines; *** IC50: half-maximal inhibitory concentration.
Miscellaneous uses of I. pes-caprae natural products.
| Compound | Pharmacological Activities | Reference |
|---|---|---|
| Potent inhibitory activity toward rat lysosomal | [ | |
|
| Inhibitory activity against ACE ** (IC50 = 180 μM) | [ |
| Inhibitory activity against ACE (IC50 = 71 μM) | ||
| Inhibitory activity against ACE (IC50 = 151 μM) | [ | |
|
| Anti-angiogenic activities (IC50 = 0.083 μM) | [ |
* IC50: half-maximal inhibitory concentration; ** ACE: angiotensin-converting enzyme; *** TNF-α: tumor necrosis factor-α; **** IL-6: interleukin 6; ***** IL-12: interleukin 12.